Literature DB >> 8880155

Malignant melanoma of the conjunctiva: occurrence and survival following surgery and radiotherapy in a Danish population.

J C Norregaard1, N Gerner, O A Jensen, J U Prause.   

Abstract

PURPOSE: To describe patient characteristics, risk of recurrence, and survival in patients with premalignant and malignant melanocytic lesions of the conjunctiva.
METHODS: In a retrospective study, 55 cases with a minimum follow-up of 10 years were reviewed.
RESULTS: The actuarial 5-and 10-year survival rates were 86% (95% Cl: 76-96%) and 73% (95% Cl: 60-87%) respectively. The 5-year risk of local recurrence was 35% (95% Cl: 21-49%), and the 10-year risk was 43% (95% Cl: 28-58%). Primary acquired melanosis with atypia was the first manifestation in 13 cases, malignant melanoma in 42 cases. No significant difference in survival and recurrence was found between the two groups or by gender, location of primary lesion, histological characteristics, or extent of surgical procedure. A minimum incidence of 0.052 cases a year per 100 000 in Denmark was calculated.
CONCLUSION: The results are estimated to represent a nationwide sample of patients. No prognostic factors of significance were identified.

Entities:  

Mesh:

Year:  1996        PMID: 8880155     DOI: 10.1007/bf00448801

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  14 in total

1.  Xeroderma pigmentosum observed in a Greenlander. Report of a case complicated by malignant melanoma of the conjunctiva.

Authors:  O A JENSEN
Journal:  Acta Ophthalmol (Copenh)       Date:  1962

2.  Conjunctival melanomas: prognostic factors a review and an analysis of a series.

Authors:  J B Crawford
Journal:  Trans Am Ophthalmol Soc       Date:  1980

3.  Conjunctival malignant melanoma in Sweden 1969-91.

Authors:  S Seregard; E Kock
Journal:  Acta Ophthalmol (Copenh)       Date:  1992-06

4.  Conjunctival melanosis and melanoma.

Authors:  R Folberg; I W McLean; L E Zimmerman
Journal:  Ophthalmology       Date:  1984-06       Impact factor: 12.079

5.  A prognostic index for patients with malignant melanoma of the conjunctiva.

Authors:  F H Stefani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

6.  Malignant melanoma of the conjunctiva.

Authors:  R Folberg; I W McLean; L E Zimmerman
Journal:  Hum Pathol       Date:  1985-02       Impact factor: 3.466

7.  Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases.

Authors:  A D Paridaens; D C Minassian; A C McCartney; J L Hungerford
Journal:  Br J Ophthalmol       Date:  1994-04       Impact factor: 4.638

8.  Conjunctival melanomas in The Netherlands: a follow-up study.

Authors:  D de Wolff-Rouendaal; J A Oosterhuis
Journal:  Doc Ophthalmol       Date:  1983-12-15       Impact factor: 2.379

9.  Therapeutic outcome of patients suffering from malignant melanomas of the conjunctiva.

Authors:  P K Lommatzsch; R E Lommatzsch; I Kirsch; P Fuhrmann
Journal:  Br J Ophthalmol       Date:  1990-10       Impact factor: 4.638

10.  Malignant melanoma of the conjunctiva.

Authors:  I J Jeffrey; D R Lucas; C McEwan; W R Lee
Journal:  Histopathology       Date:  1986-04       Impact factor: 5.087

View more
  25 in total

1.  [Analysis of ocular surface alterations following proton beam radiation in eyes with conjunctival malignant melanoma].

Authors:  H Westekemper; G Anastassiou; W Sauerwein; P Chauvel; N Bornfeld; K-P Steuhl; D Meller
Journal:  Ophthalmologe       Date:  2006-07       Impact factor: 1.059

2.  Management of conjunctival malignant melanoma: a review and update.

Authors:  James R Wong; Afshan A Nanji; Anat Galor; Carol L Karp
Journal:  Expert Rev Ophthalmol       Date:  2014-06

3.  Long-term follow-up of conjunctival melanoma treated with topical interferon alpha-2b eye drops as adjunctive therapy following surgical resection.

Authors:  Iku Kikuchi; Satoru Kase; Kan Ishijima; Susumu Ishida
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-27       Impact factor: 3.117

Review 4.  Advances in the management of conjunctival melanoma.

Authors:  Gargi K Vora; Hakan Demirci; Brian Marr; Prithvi Mruthyunjaya
Journal:  Surv Ophthalmol       Date:  2016-06-16       Impact factor: 6.048

5.  Population-based incidence of conjunctival tumours in Olmsted County, Minnesota.

Authors:  Lauren A Dalvin; Diva R Salomão; Sanjay V Patel
Journal:  Br J Ophthalmol       Date:  2018-03-06       Impact factor: 4.638

6.  Expression of matrix metalloproteinase (MMP)-2, MMP-9, and tissue inhibitor of MMP (TIMP)-1 in conjunctival melanomas and clinical implications.

Authors:  Hyoung Kyun Kim; Seoung Wan Chae; Kyung In Woo; Yoon-Duck Kim
Journal:  Jpn J Ophthalmol       Date:  2010-06-25       Impact factor: 2.447

7.  Proton radiotherapy as an alternative to exenteration in the management of extended conjunctival melanoma.

Authors:  Henrike Wuestemeyer; Wolfgang Sauerwein; Daniel Meller; Pierre Chauvel; Andreas Schueler; Klaus-Peter Steuhl; Norbert Bornfeld; Gerasimos Anastassiou
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-08-23       Impact factor: 3.117

8.  A case of conjunctival malignant melanoma with local recurrence.

Authors:  Somen Misra; Neeta Misra; Pratik Gogri; Venugopal Reddy; Akshay Bhandari
Journal:  Australas Med J       Date:  2013-06-30

Review 9.  Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma.

Authors:  Joel M Mor; Ludwig M Heindl
Journal:  Ocul Oncol Pathol       Date:  2016-12-08

Review 10.  Prognostication in eye cancer: the latest tumor, node, metastasis classification and beyond.

Authors:  T Kivelä; E Kujala
Journal:  Eye (Lond)       Date:  2012-12-21       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.